Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Brand Fights Come To India As Januvia, Galvus And Onglyza Vie For Market Share

This article was originally published in The Pink Sheet Daily

Executive Summary

Marketing of patented and branded drugs is a relatively new concept in India but going by the initial strategies put into play by multinational companies it has all the ingredients of blowing up into an all-out war in the race to capture the mind recall of doctors prescribing anti-diabetics.
Advertisement

Related Content

Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug
Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug
Merck Vows To Be In Top Five In India By 2015; Push Will Come From 13 New Launches In The Next Two Years

Topics

Advertisement
UsernamePublicRestriction

Register

PS070846

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel